PRAX
Praxis Precision Medicines, Inc.
NASDAQ · Healthcare · Biotechnology · US
$351.81
−0.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 8.6M | 2.4M | — |
| Cost of Revenue | 143.3M | 140.0K | 152.4M | 86.8M | 154.4M |
| Gross Profit | (143.3M) | (140.0K) | (143.9M) | (84.3M) | (154.4M) |
| Operating Expenses | |||||
| R&D Expense | 290.7M | 267.1M | 152.4M | 86.8M | 155.0M |
| SG&A Expense | 87.5M | 59.1M | 56.3M | 42.1M | 59.5M |
| General & Admin Expense | 87.5M | 59.1M | 56.3M | 42.1M | 59.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (143.3M) | — | (152.4M) | (86.8M) | (154.0M) |
| Total Operating Expenses | 234.9M | 326.1M | 56.3M | 42.1M | 60.5M |
| Cost and Expenses | 378.2M | 326.2M | 208.7M | 128.8M | 215.0M |
| Operating Income (EBIT) | (378.2M) | (326.2M) | (200.2M) | (126.4M) | (215.0M) |
| Non-Operating | |||||
| Interest Income | 13.3M | 22.9M | 17.3M | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 13.3M | 22.9M | 17.3M | — | — |
| Other Non-Op Income/Expense | 39.0M | 22.9M | 17.3M | 3.1M | 957.0K |
| Non-Operating Income (excl Interest) | (39.0M) | (22.9M) | (17.3M) | (3.1M) | (1.0M) |
| EBT (Pre-Tax Income) | (339.1M) | (303.3M) | (182.8M) | (123.3M) | (214.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (339.1M) | (303.3M) | (182.8M) | (123.3M) | (214.0M) |
| Earnings from Cont. Ops | (339.1M) | (303.3M) | (182.8M) | (123.3M) | (214.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (339.1M) | (303.3M) | (182.8M) | (123.3M) | (214.0M) |
| Per Share | |||||
| Basic EPS | ($12.95) | ($13.48) | ($10.21) | ($18.69) | ($69.33) |
| Diluted EPS | ($12.93) | ($13.48) | ($10.21) | ($18.69) | ($69.33) |
| Revenue Per Share | $0.00 | $0.00 | $0.48 | $0.37 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 29.1M | 22.5M | 17.9M | 6.6M | 3.1M |
| Diluted Shares Outstanding | 29.1M | 22.5M | 17.9M | 6.6M | 3.1M |
| Profitability Metrics | |||||
| EBITDA | (339.0M) | (303.1M) | (182.5M) | (122.8M) | (213.6M) |
| D&A | 119.0K | 140.0K | 358.0K | 432.0K | 419.0K |
| EBIT | (339.1M) | (303.3M) | (182.8M) | (123.3M) | (214.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026